AU2001242749A1 - Peptide derivative - Google Patents

Peptide derivative

Info

Publication number
AU2001242749A1
AU2001242749A1 AU2001242749A AU4274901A AU2001242749A1 AU 2001242749 A1 AU2001242749 A1 AU 2001242749A1 AU 2001242749 A AU2001242749 A AU 2001242749A AU 4274901 A AU4274901 A AU 4274901A AU 2001242749 A1 AU2001242749 A1 AU 2001242749A1
Authority
AU
Australia
Prior art keywords
function regulator
regulator
development
present
peptide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001242749A
Inventor
Shuji Hinuma
Masaki Hosoya
Chieko Kitada
Naoki Nishizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001242749A1 publication Critical patent/AU2001242749A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

The present invention relates to novel peptide derivatives, which are recognized as ligands to G-coupled protein receptor proteins. The peptide of the present invention can be used in (1) development of a receptor binding assay system using the expression system of the recombinant receptor protein and screening of candidates for pharmaceutical compounds, and (2) development of pharmaceutical preparations such as a neutral nerve function regulator, a circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive organ function regulator, a metabolic function regulator, a generative organ regulator or the like.
AU2001242749A 2000-03-23 2001-03-22 Peptide derivative Abandoned AU2001242749A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000087114 2000-03-23
JP2000-87114 2000-09-19
JP2000288891 2000-09-19
JP2000-288891 2000-09-19
PCT/JP2001/002278 WO2001070769A1 (en) 2000-03-23 2001-03-22 Peptide derivative

Publications (1)

Publication Number Publication Date
AU2001242749A1 true AU2001242749A1 (en) 2001-10-03

Family

ID=26588465

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001242749A Abandoned AU2001242749A1 (en) 2000-03-23 2001-03-22 Peptide derivative

Country Status (10)

Country Link
US (1) US7635751B2 (en)
EP (1) EP1270585B1 (en)
JP (1) JP4786047B2 (en)
KR (1) KR20020081466A (en)
CN (1) CN1419563A (en)
AT (1) ATE326478T1 (en)
AU (1) AU2001242749A1 (en)
CA (1) CA2403447A1 (en)
DE (1) DE60119714T2 (en)
WO (1) WO2001070769A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063892A1 (en) * 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Use of apelin
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
WO2007072980A1 (en) 2005-12-20 2007-06-28 Takeda Pharmaceutical Company Limited Novel application of apelin
RU2303454C1 (en) * 2006-06-22 2007-07-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Preparation for normalizing female reproductive function and method for its obtaining
EP1903052A3 (en) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
EP2785365B1 (en) 2011-11-28 2017-07-19 Institut National de la Sante et de la Recherche Medicale (INSERM) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
EP2802596A1 (en) * 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
JP6426107B2 (en) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド APJ receptor agonists and uses thereof
JP2016527249A (en) 2013-07-25 2016-09-08 ノバルティス アーゲー Synthetic apelin polypeptide bioconjugates
UY35670A (en) 2013-07-25 2015-02-27 Novartis Ag CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE
CN104436158A (en) * 2013-09-22 2015-03-25 华中科技大学 Application of Apelin-13 to treatment of diabetic nephropathy
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
KR20170103970A (en) 2015-01-23 2017-09-13 노파르티스 아게 Synthetic Apelin Fatty Acid Conjugate with Improved Half-life
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
SI3300500T1 (en) 2015-05-20 2020-07-31 Amgen Inc. Triazole agonists of the apj receptor
EP3416688B1 (en) 2016-02-15 2022-08-17 INSERM - Institut National de la Santé et de la Recherche Médicale Apelin for use in the treatment of post-operative cognitive dysfunction
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
EP3541804A1 (en) 2016-11-16 2019-09-25 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503145A (en) * 1992-11-17 1995-04-06 イコス　コーポレイション Novel 7-transmembrane receptor
EP1040189B1 (en) * 1997-12-24 2008-01-09 Takeda Pharmaceutical Company Limited Polypeptides, their production and use
US6475718B2 (en) * 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
AU5759399A (en) * 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative

Also Published As

Publication number Publication date
WO2001070769A1 (en) 2001-09-27
EP1270585A4 (en) 2004-12-15
ATE326478T1 (en) 2006-06-15
US7635751B2 (en) 2009-12-22
CA2403447A1 (en) 2001-09-27
DE60119714D1 (en) 2006-06-22
US20040116336A1 (en) 2004-06-17
CN1419563A (en) 2003-05-21
JP4786047B2 (en) 2011-10-05
KR20020081466A (en) 2002-10-26
EP1270585B1 (en) 2006-05-17
JP2002167397A (en) 2002-06-11
EP1270585A1 (en) 2003-01-02
DE60119714T2 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
AU2001242749A1 (en) Peptide derivative
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
NO961115L (en) Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds
DE69633175D1 (en) MULTIMINE PROTEINS
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
AU5759399A (en) Peptide derivative
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
WO2001064877A3 (en) Human schizophrenia gene
PT877803E (en) PROTEIN RECEPTOR OB AND COMPOSITIONS AND RELATED METHODS
DE68925275D1 (en) ENDOTOXIN BINDING PROTEIN AND THEIR USE
EP0638067A4 (en) Novel propoxyphene derivatives and protein and polypeptide propoxyphene derivative conjugates and labels.
EP0716591A4 (en) METHODS AND COMPOSITIONS FOR BINDING TAU AND MAP2c PROTEINS
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
EP0239311A3 (en) Mutual separation of proteins
EP0635016A4 (en) Benzodiazepine derivatives and protein and polypeptide conjugates thereof.
AU2003270010A1 (en) Transferrin fusion protein libraries
WO1999042127A3 (en) Receptor derived peptides as modulators of receptor activity
WO2001064876A3 (en) Human schizophrenia gene
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU5173996A (en) Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels
NO992531L (en) Methods of producing recombinant protein
EP0926239A3 (en) Beta-lipotropin and uses thereof
WO1999041376A8 (en) Retinoblastoma protein complexes and retinoblastoma interacting proteins